96 related articles for article (PubMed ID: 2474608)
1. Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function.
Guyre PM; Graziano RF; Vance BA; Morganelli PM; Fanger MW
J Immunol; 1989 Sep; 143(5):1650-5. PubMed ID: 2474608
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficiencies of bispecific F(ab'gamma)2 and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fc gamma receptors.
Greenman J; Hogg N; Nikoletti S; Slade C; Stevenson G; Glennie M
Cancer Immunol Immunother; 1992; 34(6):361-9. PubMed ID: 1532922
[TBL] [Abstract][Full Text] [Related]
3. Fc gamma RI blockade and modulation for immunotherapy.
Wallace PK; Keler T; Guyre PM; Fanger MW
Cancer Immunol Immunother; 1997; 45(3-4):137-41. PubMed ID: 9435857
[TBL] [Abstract][Full Text] [Related]
4. Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.
Heijnen IA; Glennie MJ; van de Winkel JG
Cancer Immunol Immunother; 1997; 45(3-4):166-70. PubMed ID: 9435865
[TBL] [Abstract][Full Text] [Related]
5. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
[TBL] [Abstract][Full Text] [Related]
6. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.
Heckel F; Turaj AH; Fisher H; Chan HTC; Marshall MJE; Dadas O; Penfold CA; Inzhelevskaya T; Mockridge CI; Alvarado D; Tews I; Keler T; Beers SA; Cragg MS; Lim SH
Commun Biol; 2022 Mar; 5(1):229. PubMed ID: 35288635
[TBL] [Abstract][Full Text] [Related]
7. Fc receptors as adaptive immunoreceptors.
Daëron M
Curr Top Microbiol Immunol; 2014; 382():131-64. PubMed ID: 25116099
[TBL] [Abstract][Full Text] [Related]
8. Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.
Hargreaves CE; Iriyama C; Rose-Zerilli MJ; Nagelkerke SQ; Hussain K; Ganderton R; Lee C; Machado LR; Hollox EJ; Parker H; Latham KV; Kuijpers TW; Potter KN; Coupland SE; Davies A; Stackpole M; Oates M; Pettitt AR; Glennie MJ; Cragg MS; Strefford JC
PLoS One; 2016; 11(3):e0145040. PubMed ID: 27007921
[No Abstract] [Full Text] [Related]
9. Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies.
Krohn S; Holtrop T; Brandsma AM; Moerer P; Nederend M; Darzentas N; Brüggemann M; Klausz K; Leusen JHW; Peipp M
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675937
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.
Sunagar R; Singh A; Kumar S
Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112761
[TBL] [Abstract][Full Text] [Related]
11. Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer.
Holtrop T; Budding K; Brandsma AM; Leusen JHW
Immunother Adv; 2022; 2(1):ltac011. PubMed ID: 36284837
[TBL] [Abstract][Full Text] [Related]
12. Current Development of Nano-Drug Delivery to Target Macrophages.
Cai D; Gao W; Li Z; Zhang Y; Xiao L; Xiao Y
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625939
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal Antibody to CD14, TLR4, or CD11b: Impact of Epitope and Isotype Specificity on ROS Generation by Human Granulocytes and Monocytes.
Kabanov DS; Grachev SV; Prokhorenko IR
Oxid Med Cell Longev; 2020; 2020():5708692. PubMed ID: 33294123
[TBL] [Abstract][Full Text] [Related]
14. CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.
Li B; Xu L; Pi C; Yin Y; Xie K; Tao F; Li R; Gu H; Fang J
Oncoimmunology; 2017; 7(1):e1380142. PubMed ID: 29296544
[TBL] [Abstract][Full Text] [Related]
15. CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases.
Akinrinmade OA; Chetty S; Daramola AK; Islam MU; Thepen T; Barth S
Biomedicines; 2017 Sep; 5(3):. PubMed ID: 28895912
[TBL] [Abstract][Full Text] [Related]
16. Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation.
Yong SB; Kim HJ; Kim JK; Chung JY; Kim YH
Sci Rep; 2017 Feb; 7():42171. PubMed ID: 28169353
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI.
Kiyoshi M; Caaveiro JM; Kawai T; Tashiro S; Ide T; Asaoka Y; Hatayama K; Tsumoto K
Nat Commun; 2015 Apr; 6():6866. PubMed ID: 25925696
[TBL] [Abstract][Full Text] [Related]
18. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
[TBL] [Abstract][Full Text] [Related]
19. Molecular therapy in head and neck oncology.
Bernier J; Bentzen SM; Vermorken JB
Nat Rev Clin Oncol; 2009 May; 6(5):266-77. PubMed ID: 19390553
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression.
Danikas DD; Karakantza M; Theodorou GL; Sakellaropoulos GC; Gogos CA
Clin Exp Immunol; 2008 Oct; 154(1):87-97. PubMed ID: 18727624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
